Lobbying Filing Details

Total Spending

$940,000

Activities

6

Lobbyists

11

Gov't Entities

72

Filing Information
Filing UUID:
c9d31c82-b417-461c-a0c5-f1e1bb4f0364
Type:
Q3 - 3rd Quarter - Report
Period:
2019 - 3rd Quarter (July 1 - Sep 30)
Date Posted:
October 18, 2019 at 7:16 PM
Income:
$0
Expenses:
$940,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Beth Anne Cole
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (6)
Activity 1
Budget/Appropriations

FDA Funding.
Public Law 115-123: Bipartisan Budget Act of 2018.
Public Law 115-141: Consolidated Appropriations Act of 2018.

Lobbyists (7)
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 2
Copyright/Patent/Trademark

Inter Partes Review (IPR) Process.
H.R.990/S.344: Hatch-Waxman Integrity Act of 2019.
Patent Settlements.
Patent Abuse.
Patent Obviousness.
BPCIA Patent Dance.
H.R.3666: STRONGER Patents Act of 2019.
Section 101 of the Patent Act.
New Chemical Entity Exclusivity (NCE).
REMEDY Act (Bill number not yet assigned).
S.440: Preserving Access to Cost Effective Drugs (PACED) Act.
H.R.2375: Preserve Access to Affordable Generics and Biosimilars Act.
S.1416: Affordable Prescriptions for Patients Act of 2019.
S.1617: Second Look at Drug Patents Act of 2019.
H.R.3199: Terminating the Extension of Rights Misappropriated Act of 2019.
Remedy of S.1209: Reforming Evergreening and Manipulation that Extends Drug Years Act.

Lobbyists (7)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JOSEPH STEWART
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 3
Medicare/Medicaid

Medicare Part D Program and Generic Drugs.
Medicare Reimbursement for Biosimilars.
Medicaid Rebate Penalty.
Medicare Part D Low Income Subsidy (LIS) Program.
Medicare Part D Coverage Gap Discount Program.
H.R.448/S.99: Medicare Drug Price Negotiation Act.
H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019.
S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019.
H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019.
S.1895: Lower Health Care Costs Act.

Lobbyists (7)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JOSEPH STEWART
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 4
Pharmacy

Implementation of Food and Drug Administration Reauthorization Act (FDARA).
Generic Drug User Fee Amendments (GDUFA).
Biosimilar User Fee Act (BsUFA).
Labeling of Generic Drugs and Biosimilars.
Country of Manufacture Labeling.
Drug Compounding.
Drug Shortages.
Product Hopping.
H.R.4398: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019.
Biosimilars Naming.
Biosimilars Insulin.
Pass Through Payments for Biosimilars.
S.1140: Protecting Access to Biosimilars Act of 2019.
H.R.4455: BIOSIM Act.
H.R.4597: Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R.4629: Star Rating for Biosimilars Act.
Prescription Drug Costs.
American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Proposed Anti-Kickback Statute (AKS) Rebates.
FDA Citizen Petitions.
Suitability Petitions.
S.660: Efficiency and Transparency in Petitions Act.
H.R.2387: STOP GAMES Act of 2019.
H.R.985: FAST Generics Act of 2019.
H.R.1506: FAIR Generics Act.
H.R.2455/S.1169: Ensuring Timely Access to Generics Act of 2019.
H.R.1503: Orange Book Transparency Act of 2019.
H.R.1520: Purple Book Continuity Act of 2019.
Drug Pricing.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
S.1416: Affordable Prescriptions for Patients Act of 2019.
H.R.2374/S.1224: Stop STALLING Act.
H.R.2376: Prescription Pricing for the People Act of 2019.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
H.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019.
H.R.465/S.102: Prescription Drug Price Relief Act of 2019.
H.R.1093/S.378: Stop Price Gouging Act.
H.R.3: Lower Drug Costs Now Act of 2019.
S.474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019.
S.440: Preserving Access to Cost Effective Drugs (PACED) Act.
S.1895: Lower Health Care Costs Act.
H.R.965/S.340: CREATES Act of 2019.
Public Law 115-123: Bipartisan Budget Act of 2018.
Risk Evaluation and Mitigation Strategies (REMS).
Pharmaceutical Exclusivity.
30-Month Stays.
Orphan Drug Exclusivity.
Biologic Exclusivity.
H.R.3379: Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act.
S.659: Biologic Patent Transparency Act.
Biologics Price Competition and Innovation Act (BPCIA).
Public Law 115-52: FDA Reauthorization Act of 2017.

Lobbyists (11)
  • CHRISTINE SIMMON
  • CHESTER DAVIS JR
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • JOSEPH STEWART
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 5
Taxation/Internal Revenue Code

User Fee Programs.

Lobbyists (6)
  • CHRISTOPHER BOWLIN
  • DAVID R. GAUGH
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JOSEPH STEWART
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 6
Trade (domestic/foreign)

General Trade Issues.
Trans-Pacific Partnership (TPP).
Biologic Exclusivity.
Pharmaceutical Exclusivity.
H.R.3379: Price Relief, Innovation, and Competition for Essential Drugs Act.
United States-Mexico-Canada Agreement (USMCA).
North American Free Trade Agreement (NAFTA).
U.S.-UK Trade Agreement.
U.S.-Japan Trade Discussions.
U.S.-India Trade Discussions.
U.S.-European Trade Negotiations.
China Tariffs.
Secretary Azar Importation Plan.

Lobbyists (9)
  • CHESTER DAVIS JR
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • JOSEPH STEWART
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • U.S. Trade Representative (USTR)
  • ... and 7 more

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.